Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Arcus Biosciences (RCUS) Net Income towards Common Stockholders: 2017-2025

Historic Net Income towards Common Stockholders for Arcus Biosciences (RCUS) over the last 7 years, with Sep 2025 value amounting to -$135.0 million.

  • Arcus Biosciences' Net Income towards Common Stockholders fell 46.74% to -$135.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$433.0 million, marking a year-over-year decrease of 60.37%. This contributed to the annual value of -$283.0 million for FY2024, which is 7.82% up from last year.
  • Arcus Biosciences' Net Income towards Common Stockholders amounted to -$135.0 million in Q3 2025, which was down 20.54% from -$112.0 million recorded in Q1 2025.
  • In the past 5 years, Arcus Biosciences' Net Income towards Common Stockholders registered a high of $279.5 million during Q4 2021, and its lowest value of -$135.0 million during Q3 2025.
  • In the last 3 years, Arcus Biosciences' Net Income towards Common Stockholders had a median value of -$86.5 million in 2023 and averaged -$83.7 million.
  • Examining YoY changes over the last 5 years, Arcus Biosciences' Net Income towards Common Stockholders showed a top increase of 637.62% in 2021 and a maximum decrease of 4,379.64% in 2021.
  • Over the past 5 years, Arcus Biosciences' Net Income towards Common Stockholders (Quarterly) stood at $279.5 million in 2021, then tumbled by 123.97% to -$67.0 million in 2022, then decreased by 20.90% to -$81.0 million in 2023, then declined by 16.05% to -$94.0 million in 2024, then tumbled by 46.74% to -$135.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$135.0 million for Q3 2025, versus -$112.0 million for Q1 2025 and -$94.0 million for Q4 2024.